ValGenesis and Célere Partner to Deliver Advanced Digital Validation Solutions

12 June 2024 | Wednesday | News

Collaboration aims to enhance operational performance and regulatory compliance for life sciences companies in the U.S. and Europe through innovative digital validation platforms.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Célere, a life sciences-focused consultancy in California, have partnered to deliver best-in-class digital validation solutions for companies across the U.S. and Europe.

Célere partners with life sciences and healthcare institutions to help them improve operational performance and regulatory compliance through digitized cGMP facilities, cGxP computer systems validation, clinical trials and data management, quality, compliance, and regulatory processes.

ValGenesis is the industry innovator of digitized validation. The company’s platform, which includes its flagship VLMS offering, is used in over 100,000 GMP systems worldwide, helping life sciences companies advance their digital transformation strategy, enforce compliance, and enable standardization with 100% digital, risk-based validation software.

ValGenesis and Célere are enabling customers with robust manufacturing intelligence solutions from ValGenesis, such as ValGenesis VLMS, the industry standard digital validation platform for computer software assurance, commissioning and qualification, cleaning validation, and more.

“We are excited to partner with Célere at a time when the industry is on the precipice of a new digital-first technology-led era,” says Bo Olsen, ValGenesis’ SVP of Partners. “Our companies are committed to meeting customers’ exacting needs through proven solutions that drive new levels of digital transformation, compliance, and corporate efficiency.”

“ValGenesis has been a critical accelerator for our validation engineers over many years. Its use has resulted in measurable cost savings and a distinct competitive advantage for our shared global clients,” says Mike Nourie, President of Celere, Inc.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close